Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization

Xenobiotica

Volumn 27, Issue 1, 1997, Pages 111-125

  Gilham, D E ^a   Cairns, W ^a   Paine, M J I ^a   Modi, S ^b   Poulsom, R ^c   Roberts, G C K ^b   Wolf, C R ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYTOCHROME P450 ISOENZYME; QUINIDINE; RECOMBINANT ENZYME;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DETOXIFICATION; DRUG METABOLISM; DRUG SENSITIVITY; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC POLYMORPHISM; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LIVER; MITOCHONDRIAL RESPIRATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSONISM;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ADULT; BRAIN; CYTOCHROME P-450 CYP2D6; FETUS; HUMANS; IN SITU HYBRIDIZATION; MAGNETIC RESONANCE SPECTROSCOPY; MICROSOMES, LIVER; RNA, MESSENGER;

ANIMALIA;

EID: 0031014344     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240802     Document Type: Article

References (41)

1. ARORA, P. K., RIACHI, N. J., HARIK, S. I. and SAYRE, L. M., 1988, Chemical oxidation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its in vivo metabolism in rat brain and liver. Biochemical and Biophysical Research Communications, 152, 1339-1347.
2. BALLARD, P. A., TETRUD, J. W. and LANGSTON, J. W., 1985, Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology, 35, 949-956.
3. BARBEAU, A., CLOUTIER, T., ROY, M., PLASSE, L., PARIS, S. and POIRER, J., 1987, Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet, ii, 1213-1216.
4. BERTILSSON, L., ALM, D., DE LAS CARRERAS, C., WIDEN, J., EDMAN, G. and SCHALLING, D., 1989, Debrisoquine hydroxylation and personality. Lancet, ii, 555.
5. BORLAK, J. T., HARSANY, V., SCHNEBLE, H. and HAEGELE, K. D., 1994, pNAT and CYP2D6 gene polymorphism in epileptic patients. Biochemical Pharmacology, 48, 1717-1720.
6. CASHMAN, J. R. and ZIEGLER, D. M., 1985, Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) by various liver preparations. Molecular Pharmacology, 29, 163-167.
7. CHIBA, K., KUBOTA, E., MIYAKAWA, T., KATO, Y. and ISHIZAKI, T., 1988, Characterization of hepatic microsomal metabolism as an in vivo detoxification pathway of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyndine in mice. Journal of Pharmacology and Experimental Therapeutics, 246, 1108-1115.
8. COLEMAN, T., ELLIS, S. W., MARTIN, I. J., LENNARD, M. S. and TUCKER, G. T., 1996, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 - implications for susceptibility to Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 277, 685-690.
9. FONNE-PFISTER, R, BARGETZI, M. J. and MEYER, U. A., 1987, MPTP, the neurotoxin inducing Parkinson's Disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylation. Biochemical and Biophysical Research Communications, 148, 1144-1150.
10. FORRESTER, L. M., HENDERSON, C. J., GLANCEY, M. J., BACK, D. J., PARK, B. K., BALL, S. E., KITTERINGHAM, N. R., MCLAREN, A. W., MILES, J. W., SKETT, P. and WOLF, C. R., 1992, Relative expression of cytochrome P450 isozymes in human liver and association with the metabolism of drugs and xenobiotics. Biochemical Journal, 281, 359-368.
11. GONZALEZ, F. J., SKODA, R. C., KIMURA, S., UMENO, M., ZANGER, U. M., NEBERT, D. W., GELBOIN, H. V., HARDWICK, J. P. and MEYER, U. A., 1988, Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature, 331, 442-446.
12. GOUGH, A. C., MILES, J. S., MOSS, J. E., GAEDIGK, A., EICHELBAUM, M. and WOLF, C. R., 1990, Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature, 347, 773-776.
13. GUT, J., CATIN, T., DAYER, P., KRONBACH, T., ZANGER, U. and MEYER, U. A., 1986, Debrisoquine/ sparteine-type polymorphism of drug oxidation. Journal of Biological Chemistry, 261, 11734-11743.
14. HAGLUND, L., KOHLER, C., HAAPARANTA, T., GOLDSTEIN, M. and GUSTAFSSON, J. A., 1984, Presence of NADPH-cytochrome P450 reductase in central catecholaminergic neurones. Nature, 307, 259-262.
15. HAYES, J. D. and WOLF, C. R., 1990, Molecular mechanisms of drug resistance. Biochemical Journal, 272, 281-295.
16. JIMENEZ-JIMENEZ, F. J., TABERNERO, C., MENA, M. A., GARCIA DE YEBENES, J., GARCIA DE YEBENES, M. J., CASAREJOS, M. J., PARDO, B., GARCIA-AGUNDEZ, J. A., BENITEZ, J., MARTINEZ, A. and GARCIA-ASENJO, J. A. L., 1991, Acute effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in a model of rat designated a poor metabolizer of debrisoquine. Journal of Neurochemistry, 57, 81-87.
17. KRONBACH, T., MATHYS, D., GUT, J., CATIN, T. and MEYER, U. A., 1987, High-performance liquid chromatography assays for bufuralol 1′-hydroxylase, debrisoquine 4′-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry, 162, 24-32.
18. KUTTY, R. K., SANTOSTASI, G., HORNG, J. and KRISHNA, G., 1991, MPTP-induced ATP depletion and cell death in neuroblastoma x glioma hybrid NG 108-15 cells: protection by glucose and sensitization by tetraphenylborate. Toxicology and Applied Pharmacology, 107, 377-388.
19. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
20. MODI, S., PAINE, M. J., SUTCLIFFE, M. J., LIAN, L.-Y., PRIMROSE, W. U., WOLF, C. R. and ROBERTS, G. C. K., 1996, Substrate binding to cytochrome P450 2D6. Biochemistry, 35, 4540-4550.
21. MOLDEUS, P., HOGBERG, J. and ORRENIUS, S., 1978, Isolation and use of liver cells. Methods in Enzymology, LII, part C, 60-71.
22. 3H] GBR-12935 binding sites. Archives of Biochemistry and Biophysics, 276, 424-432.
23. PAI, K. S. and RAVINDRANATH, V., 1991, Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices. Brain Research, 555, 239-244.
24. PAINE, M. J. I., GILHAM, D., ROBERTS, G. C. K. and WOLF, C. R., 1996, Functional high level expression of cytochrome P450 CYP2D6 using baculoviral expression systems. Archives of Biochemistry and Biophysics, 328, 143-150.
25. POIRER, J., ROY, M., CAMPANELLA, G., CLOUTIER, T. and PARIS, S., 1987, Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet, ii, 386.
26. PRICE-EVANS, D. A., MAHGOUB, A., SLOAN, T. P., IDLE, J. R. and SMITH, R. L., 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics, 17, 102-105.
27. SALACH, J. I., SINGER, T. P., CASTAGNOLI, JR, N. and TREVOR, A., 1984, Oxidation of the neurotoxic amine 1-mehtyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP. Biochemical and Biophysical Research Communications, 125, 831-835.
28. SENIOR, P. V., CRITCHLEY, D. R., BECK, F., WALKER, R. A. and VARLEY, J. M., 1988, The localisation of laminin mRNA and protein in the postimplantation embryo and placenta of the mouse: an in situ hybridisation and immunohistochemical study. Development, 104, 431-446.
29. SHAHI, G. S., DAS, N. P. and MOOCHHALA, S. M., 1990, Parkinson's disease and cytochrome P450: a possible link? Medical Hypothesis, 32, 277-282.
30. SHINKA, T., CASTAGNOLI, JR. N., WU, E. Y., HOAG, M. K. P. and TREVOR, A. J., 1987, Cation-exchange high performance liquid chromatography assay for the nigrostriatal oxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridme and its monoamine oxidase B generated metabolites in brain tissues. Journal of Chromatography, 398, 279-287.
31. SINDRUP, S. H., POULSEN, L., BROSEN, K., ARENDT-NIELSEN, L. and GRAM, L. F., 1993, Are poor metabolisers of sparteine/debrisoqume less pain tolerant than extensive metabolisers ? Pain, 537, 335-349.
32. SMITH, C. A. D., GOUGH, A. C., LEIGH, P. K., SUMMERS, B. A., HARDING, A. E., MARANGANORE, D. M., STURMAN, S. G., SCHAPIRA, A. H. V., WILLIAMS, A. C., SPURR, N. K. and WOLF, C. R., 1992, Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet, 339, 1375-13771
33. SPENCER, P. S., LUDOLPH, A. C. and KISBY, G. E., 1993, Neurologic diseases associated with use of plant components with toxic potential. Environmental Research, 62, 106-113.
34. SUTCLIFFE, R. L. G. and MEARA, J. R., 1995, Parkinson's disease epidemiology in the Northampton District, England, 1992. Acta Neurologica Scandinavia, 92, 443-450.
35. TANNER, C. M., 1991, Abnormal liver enzyme-mediated metabolism in Parkinson's disease: a second look. Neurology, 41 (suppl. 2), 89-91.
36. TIPTON, K. F., MCCRODDEN, J. M. and SULLIVAN, J. P., 1993, Metabolic aspects of the behavior of MPTP and some analogues. Advances in Neurology, 60, 186-192.
37. TUCKER, G. T., 1994, Clinical implications of genetic polymorphism in drug metabolism. Journal of Pharmacy and Pharmacology, 46 (suppl. 1), 417-424.
38. TYNDALE, R. F., SUNAHARA, R., INABA, T., KALOW, W., GONZALEZ, F. J. and NIZIK, H. B., 1991, Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology, 40, 63-68.
39. WEISSMAN, J., TREVOR, A., CHIBA, K., PETERSON, L. A., CALDERA, P., CASTANOLI, JR, N. and BAILLIE, T., 1985, Metabolism of the nigrostriatal toxin 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine by liver homogenate fractions. Journal of Medicinal Chemistry, 28, 997-1001.
40. WOLF, C. R., 1990, Metabolic factors in cancer susceptibility. Cancer Surveys, 9, 437-474.
41. ZANDVLIET, D. W. J., HANBY, A. M., AUSTIN, C. A., MARSH, K. L., CLARK, I. B. N., WRIGHT, N. A. and POULSOM, R., 1996, Analysis of foetal expression sites of human type II DNA topoisomerase α and β mRNAs by in situ hybridisation. Biochemical Biophysica Acta, 1307, 239-247.